Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1441785

Worldwide research trends in Crohn's disease treatment over the past two decades: a bibliometric analysis

Provisionally accepted
Likang Xu Likang Xu 1Jinzhao Zou Jinzhao Zou 2*Chao Sun Chao Sun 3*Gong Chen Gong Chen 3*Sujun Gao Sujun Gao 1*
  • 1 Medical College, Yangzhou University, Yangzhou, China
  • 2 Department of Medical Imaging, Jiangsu Subei People's Hospital, Medical College, Yangzhou University, Yangzhou, Jiangsu Province, China
  • 3 Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    The treatment of Crohn's disease (CD) has received widespread attention in clinical practice, but there is currently a lack of quantitative evaluation of the literature published in this field. This study aimed to describe the development trends and research hotspots of CD treatment through bibliometric analysis. Methods: Publications related to CD treatment published from 2004 to 2023 were searched in the WoSCC. Microsoft Office Excel 2021 was used for the analysis and visualization of the annual number of publications. CiteSpace was used to visualize the collaboration networks of authors, institutions, and countries, as well as to construct a reference timeline visualization map and identify keywords with the strongest citation bursts. Results: The bibliometric analysis included 25,608 publications between 2004 and 2023. The most productive year was 2021. The United States of America (n=7891) and the University of California System (n=939) are the country and institution with the most published papers, respectively. Among the 97,564 authors, Peyrin-Biroulet, Laurent (n=424) published the most articles. The core journals were Inflammatory Bowel Diseases, Journal of Crohns & Colitis, Alimentary Pharmacology &Therapeutics, etc. The timeline view showed that "#5 JAK Inhibitor" was the most recent topic. The keywords that burst and persist from 2020 to 2023 include "ustekinumab" and "vedolizumab".An increasing number of researchers are dedicating their efforts to exploring the treatment of CD, with the USA making the largest contribution to this field. Currently, the research hotspots predominantly involve drug therapy including ustekinumab, vedolizumab, and JAK inhibitors. Our study provides valuable information for scholars studying CD treatment.

    Keywords: Crohn's disease, bibliometric analysis, Web of Science, Treatment, Citespace

    Received: 31 May 2024; Accepted: 23 Sep 2024.

    Copyright: © 2024 Xu, Zou, Sun, Chen and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jinzhao Zou, Department of Medical Imaging, Jiangsu Subei People's Hospital, Medical College, Yangzhou University, Yangzhou, 225001, Jiangsu Province, China
    Chao Sun, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou, 225001, Jiangsu Province, China
    Gong Chen, Northern Jiangsu People's Hospital, Yangzhou University, Yangzhou, 225001, Jiangsu Province, China
    Sujun Gao, Medical College, Yangzhou University, Yangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.